Human Cytomegalovirus: Purification of Enveloped Virions and Dense Bodies

References

1. Barzilai R., Lazarus L. H., Goldblum N. 1972; Viscosity‒density gradient for purification of foot-and-mouth disease virus. Archiv fur die gesamte Virusforschung 36:141–146
   [Google Scholar]
2. Craighead J. E., Kanich R. E., Almeida J. D. 1972; Nonviral microbodies with viral antigenicity produced in cytomegalovirus-infected cells. Journal of Virology 10:766–775
   [Google Scholar]
3. Fiala M., Honess R. W., Heiner D. C., Heine J. E., Murnane J., Wallace R., Guze L. B. 1976; CytOmegalovirus proteins. I. Polypeptides of virions and dense bodies. Journal of Virology 19:243–254
   [Google Scholar]
4. Huang E. S., Chen S. T., Pagano J. S. 1973; Human cytomegalovirus I. Purification and characterisation of viral DNA. Journal of Virology 12:1473–1481
   [Google Scholar]
5. Jacobs J. P., Jones C. M., Baille J. P. 1970; Characteristics of a human diploid cell designated MRC–5. Nature, London 227:168–170
   [Google Scholar]
6. Obijeski J. F., Marchenko A. T., Bishop D. H. L., Cann B. W., Murphy F. A. 1974; Comparative electrophoretic analysis of the virus proteins of four rhabdoviruses. Journal of General Virology 22:21–33
   [Google Scholar]
7. Pagano J. S. 1976; Prevention of infections with cytomegalovirus. Yale Journal of Biology and Medicine 49:59–62
   [Google Scholar]
8. Rowe W. P., Hartley J. W., Waterman S., Turner H. C., Huebner R. J. 1956; Cytopathic agent resembling human salivary gland virus recovered from tissue cultures of human adenoids. Proceedings of the Society for Experimental Biology and Medicine 92:418–424
   [Google Scholar]
9. Sarov I., Abady I. 1975; The morphogenesis of human cytomegalovirus. Isolation and polypeptide characterisation of cytomegalovirions and dense bodies. Virology 66:464–473
   [Google Scholar]
10. Stinski M. F. 1976; Human cytomegalovirus: glycoproteins associated with virions and dense bodies. Journal of Virology 19:594–609
    [Google Scholar]
11. Weller T. H. 1971; The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. New England Journal of Medicine 285:203–214–267–274
    [Google Scholar]